Blood Protein Biomarkers as Diagnostic Tool for Ischemic Stroke: A Systematic Review

Monbailliu, Thomas; Goossens, Joline; Hachimi-Idrissi, Saı̈d

doi:10.2217/bmm-2016-0232

Cited by 42 publications

(53 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is the consequence of pathophysiological processes occurring with different intensity in various etiopathological types of stroke, additionally complicated by different course of these processes in individual patients being the result of differences in their metabolism, age, ethnic differences, or presence of coexisting diseases. It has been postulated that the greatest chance for clinical application can have diagnostic panels composed of biomarkers characteristic for specific types of stroke [216,218]. Biomarkers in these panels should be representative for pathophysiological processes, such as oxidative stress, necrotic and apoptotic cell death, BBB disintegration and brain edema, inflammatory response, and thrombosis.…”

Section: Perspectives For Identification Of Effective Biomarkers Of Tmentioning

confidence: 99%

Neurovascular Unit as a Source of Ischemic Stroke Biomarkers—Limitations of Experimental Studies and Perspectives for Clinical Application

Steliga

Kowiański

Czuba

et al. 2019

Transl. Stroke Res.

View full text Add to dashboard Cite

Cerebral stroke, which is one of the most frequent causes of mortality and leading cause of disability in developed countries, often leads to devastating and irreversible brain damage. Neurological and neuroradiological diagnosis of stroke, especially in its acute phase, is frequently uncertain or inconclusive. This results in difficulties in identification of patients with poor prognosis or being at high risk for complications. It also makes difficult identification of these stroke patients who could benefit from more aggressive therapies. In contrary to the cardiovascular disease, no single biomarker is available for the ischemic stroke, addressing the abovementioned issues. This justifies the need for identifying of effective diagnostic measures characterized by high specificity and sensitivity. One of the promising avenues in this area is studies on the panels of biomarkers characteristic for processes which occur in different types and phases of ischemic stroke and represent all morphological constituents of the brains' neurovascular unit (NVU). In this review, we present the current state of knowledge concerning already-used or potentially applicable biomarkers of the ischemic stroke. We also discuss the perspectives for identification of biomarkers representative for different types and phases of the ischemic stroke, as well as for different constituents of NVU, which concentration levels correlate with extent of brain damage and patients' neurological status. Finally, a critical analysis of perspectives on further improvement of the ischemic stroke diagnosis is presented.

show abstract

Section: Perspectives For Identification Of Effective Biomarkers Of Tmentioning

confidence: 99%

Neurovascular Unit as a Source of Ischemic Stroke Biomarkers—Limitations of Experimental Studies and Perspectives for Clinical Application

Steliga

Kowiański

Czuba

et al. 2019

Transl. Stroke Res.

View full text Add to dashboard Cite

show abstract

“…Blood, urine, salivary, and even CSF-derived biomarkers help with diagnosis, prognosis, and therapeutic monitoring for many other diseases where time is less critical. While more than 150 different candidate stroke biomarkers have been investigated in relation to various aspects of the stroke condition, from diagnosis to long-term prognosis, [58][59][60][61][62][63] none has made it into routine clinical practice.…”

Section: Biomarkersmentioning

confidence: 99%

Applications of Nanotechnology in the Diagnosis and Therapy of Stroke

Landowski

Niego

Sutherland

et al. 2019

Semin Thromb Hemost

View full text Add to dashboard Cite

Stroke is a leading cause of death and disability worldwide. The classification of stroke subtypes is difficult but critical for the prediction of clinical course and patient management, and limited treatment options are available. There is an urgent need for improvements in both diagnosis and therapy. Strokes have rapidly evolving phases of damage involving unique compartments of the brain, which imposes severe limitations for current diagnostic and treatment procedures. The rapid development of nanotechnology in other areas of modern medicine has ignited a widespread interest in its potential for the field of stroke. An important feature of nanoparticles is the relative ease in which their structures and surface chemistries can be modified for specific and potentially multiple, simultaneous purposes. Nanoparticles can be synthesized to carry and deliver therapeutics to specific cellular or subcellular compartments; they can be engineered to provide enhanced contrast for imaging based on the detection of changes in the blood flow; or possess ligand-specific chemistries which can facilitate diagnosis and monitor the treatment response. More specifically for a stroke, nanoparticles can be engineered to release their payload in response to the distinct extracellular processes occurring around the clot and in the ischemic penumbra, as well as aid in the detection of pathological hallmarks present at various stages of stroke progression. These capacities allow targeted release of disease-modifying agents in the affected brain tissue, increasing treatment efficacy, and limiting unwanted side effects. While nanospheres, liposomes, and mesoporous nanostructures all emerge as future prospects for stroke treatment and diagnosis, much of this potential is yet to be clinically realized. This review outlines aspects of nanotechnology identified as having potential to revolutionize the field of stroke.

show abstract

“…Ischemic stroke is characterised by high morbidity and mortality. Over recent years, a number of potential biochemical markers associated with stroke had been reported [2]. Yet still, the current clinical practice lacked a rapid, reliable, sensitive, and specific serological test or indicator to assess risks of patients developing ischemic stroke.…”

Section: Introductionmentioning

confidence: 99%

The Length and Distribution of Plasma Cell-Free DNA Fragments in Stroke Patients

Cui

Du²,

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

A number of studies have shown that plasma cell-free DNA is closely related to the risk of stroke, but the fragmentation status of plasma cell-free DNA and its clinical application value in ischemic stroke are still unclear. In this study, 48 patients with new ischemic stroke and 20 healthy subjects were enrolled. The second-generation high-throughput sequencing technique was used to study the plasma cell-free fragment length and regional distribution of the subjects. As noted in our results, the ratio of plasma cell-free DNA fragments in the disease group was significantly greater than that of the healthy group in the 300–400 bp range; conversely for fragments at the 75–250 bp range, the ratio of plasma cell-free DNA fragments in the patient group was apparently lower than that of the healthy group. In-depth analysis of the proportion of fragments distributed on each component of the genome was carried out. Our results recorded that the plasma cell-free DNA fragments in the disease group were inclined to the EXON, CpG islands, and ALU regions in contrast to that of the healthy group. In particular, fragments within the 300–400 bp range of the disease group were enrichment in the regions of EXON, INTRON, INTERGENIC, LINE, Fragile, ALU, and CpG islands. In summary, our findings suggested that the intracellular DNA degradation profiles could be applied to distinguish the stroke group and the healthy group, which provided a theoretical basis for the clinical diagnosis and prognosis of stroke by profiling the characteristic of plasma cell-free DNA fragments.

show abstract

Blood Protein Biomarkers as Diagnostic Tool for Ischemic Stroke: A Systematic Review

Abstract: The blood protein biomarkers, brain natriuretic peptide (BNP) and S100B, were promising biomarkers in diagnosing ischemic stroke. They could be used in cases of diagnostic uncertainty and/or when less experienced healthcare personnel are involved.

Cited by 42 publications

References 58 publications

Neurovascular Unit as a Source of Ischemic Stroke Biomarkers—Limitations of Experimental Studies and Perspectives for Clinical Application

Neurovascular Unit as a Source of Ischemic Stroke Biomarkers—Limitations of Experimental Studies and Perspectives for Clinical Application

Applications of Nanotechnology in the Diagnosis and Therapy of Stroke

The Length and Distribution of Plasma Cell-Free DNA Fragments in Stroke Patients

Contact Info

Product

Resources

About